Castle Biosciences (CSTL): Evaluating Valuation as New Melanoma Test Data Gains Attention at Major Oncology Congress

Castle Biosciences (CSTL) has just shared new data on its DecisionDx-Melanoma test, showing it can help doctors make more informed decisions about sentinel lymph node biopsies and recurrence risks for ...
Medscape

Genomic Test Predicts Sentinel Node Metastasis in Melanoma

A gene expression-based test identifies patients with primary cutaneous melanoma at a lower or higher risk for sentinel lymph ...

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

DecisionDx-Melanoma continues to demonstrate strong performance in helping physicians make more informed, risk-aligned ...
Healio

DecisionDx test can help identify sentinel lymph node risk

Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
EurekAlert!

New liquid biopsy test to ID lymph node metastasis in early-stage T1 colorectal cancer

This new, blood-based test successfully identifies individuals with lymph node metastasis associated with high-risk T1 colorectal cancer and potentially could help people with non-high-risk ...